Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 11;7:624576. doi: 10.3389/fmed.2020.624576

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Elena-Pérez, Heredero-Jung, García-Sánchez, Estravís, Martin, Ramos-González, Triviño, Isidoro-García, Sanz and Dávila.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Peripheral blood eosinophil counts and (B) IL5RA expression levels in pretreatment and after 3 months of benralizumab treatment. The median of each group is also shown. (C) Correlation between IL5RA expression levels and peripheral blood eosinophil counts at pretreatment and after 3 months of benralizumab treatment. Pearson's correlation coefficient in the pretreatment is also shown. Each symbol represents a patient ( Patient 1; Patient 2; Patient 3; Patient 4; Patient 5). The filled symbols correspond to the pretreatment and the empty symbols to after 3 months of benralizumab treatment.

Inline graphic — (A) Peripheral blood eosinophil counts and (B) IL5RA expression levels in pretreatment and after 3 months of benralizumab treatment. The median of each group is also shown. (C) Correlation between IL5RA expression levels and peripheral blood eosinophil counts at pretreatment and after 3 months of benralizumab treatment. Pearson's correlation coefficient in the pretreatment is also shown. Each symbol represents a patient ( Patient 1; Patient 2; Patient 3; Patient 4; Patient 5). The filled symbols correspond to the pretreatment and the empty symbols to after 3 months of benralizumab treatment.